Bioconvergence

Last updated

Bioconvergence is a multidisciplinary method in life science. It uses the synergy between biotech, engineering and computerized systems to address unresolved challenges, like speeding up diagnostic processes, creating more advanced materials, or advancing drug development. [1] Along with healthcare, bioconvergence assists in the improvement of various sectors such as agriculture, energy, food, security, climate, etc. [2] McKinsey research predicts that more than half of the impact of bioconvergence will be outside of healthcare, in areas such as agriculture, aquaculture and food, consumer products and services (such as DNA and microbiome testing), novel materials, chemistry and energy. According to McKinsey, bioconvergence solutions currently being developed could have an economic impact of up to US$ 4 trillion per year over the next 10 to 20 years. [3]

Contents

Implications

Bioconvergence uses methods from disciplines such as biology, chemistry, physics, engineering, medicine, mathematics, agriculture, computational sciences and artificial intelligence (AI), in order to solve challenges across several sectors.

Healthcare

A lung on a chip, close up Lung-on-a-chip-wyss.jpg
A lung on a chip, close up

Bioconvergence technologies in healthcare include translational medicine, enabling the extraction of hidden insights from massive data sets; neuromorphic computing, who seeks to emulate the biological neural structure of the brain to achieve unparalleled levels of processing performance and energy efficiency; creation of digital twins for clinical trials; and biochips such as organ on a chip" (OOC). [4] Other implications of bioconvergence include new methods of using nanorobotics for drug delivery, regenerative medicine, diagnostics and biological sensors, optogenetics, bioelectronics, engineered "living" materials, and more. [5] According to Belén Garijo, CEO of Merck, bioconvergence can also bring about the potential of personalized medicine". [6]

Food and agriculture

A vertical farm in Finland IFarm.fi Vertical farm Finland.jpg
A vertical farm in Finland

Traditional agriculture relies on land, water, and a suitable climate. In the future, based on bioconvergence led research and technologies, foods could be manufactured anywhere in labs and indoor vertical farms. This could fundamentally reshape the agricultural sector, international trade, and migration, as well as people's relationships with land, animals, and food. [7]

Applications also include innovative new ways to conduct breeding of animals and plants using molecular or genetic markers that are many times quicker than established selective-breeding methods; new, more precise tools for the genetic engineering of plants; fast-developing work using the microbiome of plants, soil, animals, and water to improve the quality and productivity of agricultural production; and the development of alternative proteins, including cultured meat, alternative eggs, and alternative milk. [3]

Energy, climate and advanced materials

Bioconvergence could transform the natural resource sector through new ways of making and obtaining raw materials and fuels, as well as new manufacturing techniques. This could potentially ease pressure on natural resources. [7]

History

The term "bioconvergence" was used in 2005 to describe the integration of bio and information-technologies into the healthcare industry. [8] Since 2020, it has gained wider recognition.

In April 2020, The European Investment Bank and the Israel Innovation Authority concluded a cooperation agreement to jointly pursue investments in the globally emerging domain of bioconvergence. [9]

In March 2021, the US National Intelligence Council (NIC), which bridges the United States Intelligence Community with policy makers in the US, published a research paper on the "Future of Biology", concluding that "During the next 20 years, a more multidisciplinary and data-intensive approach to life sciences will shift our understanding of and ability to manipulate living matter. These disciplines, combined with cognitive science, nanotechnology, physics, and others, are propelling new leaps in our understanding. It is anticipated that the collective application of these diverse technologies to the life sciences—known as bioconvergence— will accelerate discovery and predictability in biotech design and production." [10] [ excessive quote ]

In September 2021, CELLINK Life Sciences, a Swedish publicly traded company that commercialized the first bio-based ink in 2016, changed its group name to BICO Group, short for "bioconvergence." It is building a portfolio that blends biology, engineering and computer science technologies and considering acquisition opportunities in bioconvergence technology companies. [11]

In May 2022, Israel launched a 5-year national plan worth NIS  435 million (US$ 127 million) to boost research and development in bioconvergence. [12] Also in May 2022, Ben-Gurion University of the Negev (BGU) and Soroka Medical Center announced a strategic collaboration for the development of novel technologies in the field of bioconvergence. [13]

In October 2022, Japan announced that it will establish a global center of bioconvergence innovation in the Okinawa Institute of Science and Technology. It will be supported by a grant from the Japan Science and Technology Agency JST Program on Open Innovation Platform for Academia-Industry Co-Creation. [14]

According to a McKinsey report on public policy and "Biological innovations for complex problems", The Israel Innovation Authority, responsible for Israel's innovation policy and financial support for Research and Development technology driven companies, is "investing in bioconvergence technologies to ensure that professionals in biology, computer science, mathematics, engineering, and nanoscience work seamlessly together". [15] [ excessive quote ] The Israel Innovation Authority views bioconvergence as potentially "one of the next significant growth engines of Israeli high-tech". [16]

Market

According to research company Grand View Research, the global bioconvergence market was valued at USD 110.9 billion in 2021 and is anticipated to expand at a compound annual growth rate (CAGR) of 7.4% from 2022 to 2030. The significant market growth can be attributed to the increasing elderly population and the accelerating stem cell technology for the fixing of injured cells, tissues, and organs. [2] A McKinsey report in 2020 suggests that a pipeline of over 400 scientifically feasible use cases are already visible, and that these applications alone could have direct economic impact of up to US$ 4 trillion per year over the next 10 to 20 years. [3]

Related Research Articles

<span class="mw-page-title-main">Biotechnology</span> Use of living systems and organisms to develop or make useful products

Biotechnology is a multidisciplinary field that involves the integration of natural sciences and engineering sciences in order to achieve the application of organisms, cells, parts thereof and molecular analogues for products and services.

<span class="mw-page-title-main">Technion – Israel Institute of Technology</span> Israeli research university in Haifa

The Technion – Israel Institute of Technology is a public research university located in Haifa, Israel. Established in 1912 under the dominion of the Ottoman Empire, the Technion is the oldest university in the country.

Science and technology in Israel is one of the country's most developed sectors. Israel spent 4.3% of its gross domestic product (GDP) on civil research and development in 2015, the highest ratio in the world. In 2019, Israel was ranked the world's fifth most innovative country by the Bloomberg Innovation Index. It ranks thirteenth in the world for scientific output as measured by the number of scientific publications per million citizens. In 2014, Israel's share of scientific articles published worldwide (0.9%) was nine times higher than its share of the global population (0.1%).

<span class="mw-page-title-main">Genome Valley</span> Life Sciences in Telangana, India

Genome Valley is an Indian high-technology business district spread across 2,000-acre (8.1 km2)/(3.1 sq mi) in Hyderabad, India. It is located across the suburbs, Turakapally, Shamirpet, Medchal, Uppal, Patancheru, Jeedimetla, Gachibowli and Keesara. The Genome Valley has developed as a cluster for Biomedical research, training and manufacturing. Genome Valley is now into its Phase III, which is about 11 km from the Phase I and II with the total area approximately 2,000-acre (8.1 km2).

<span class="mw-page-title-main">Biological engineering</span> Application of biology and engineering to create useful products

Biological engineering or bioengineering is the application of principles of biology and the tools of engineering to create usable, tangible, economically viable products. Biological engineering employs knowledge and expertise from a number of pure and applied sciences, such as mass and heat transfer, kinetics, biocatalysts, biomechanics, bioinformatics, separation and purification processes, bioreactor design, surface science, fluid mechanics, thermodynamics, and polymer science. It is used in the design of medical devices, diagnostic equipment, biocompatible materials, renewable energy, ecological engineering, agricultural engineering, process engineering and catalysis, and other areas that improve the living standards of societies.

Jeonbuk National University is one of ten Flagship Korean National Universities founded in 1947, located in Jeonju, South Korea. Jeonbuk National University has been ranked 551–560th in the world by QS Top Universities Ranking in 2023.

<span class="mw-page-title-main">University of Minnesota College of Biological Sciences</span>

The College of Biological Sciences (CBS) is one of seven freshman-admitting colleges at the University of Minnesota. Established in 1869 as the College of Science, the College of Biological Science is now located across both the Minneapolis and the St. Paul campuses. As of June 29, 2023, the dean of the College of Biological Sciences is Dr. Saara J DeWalt.

<span class="mw-page-title-main">Patrick Soon-Shiong</span> American billionaire physician, CEO & philanthropist (b. 1952)

Patrick Soon-Shiong is an American transplant surgeon, billionaire businessman, bioscientist, and media proprietor. He is the inventor of the drug Abraxane, which became known for its efficacy against lung, breast, and pancreatic cancer. Soon-Shiong is the founder of NantWorks, a network of healthcare, biotech, and artificial intelligence startups; an adjunct professor of surgery and executive director of the Wireless Health Institute at the University of California, Los Angeles; and a visiting professor at Imperial College London and Dartmouth College. Soon-Shiong has published more than 100 scientific papers and has more than 230 issued patents worldwide on advancements spanning numerous fields in technology and medicine.

<span class="mw-page-title-main">California Institute for Quantitative Biosciences</span>

The California Institute for Quantitative Biosciences (QB3) is a nonprofit research and technology commercialization institute affiliated with three University of California campuses in the San Francisco Bay Area: Berkeley, San Francisco, and Santa Cruz. QB3's domain is the quantitative biosciences: areas of biology in which advances are chiefly made by scientists applying techniques from physics, chemistry, engineering, and computer science.

China has seen double-digit growth in its biotechnology industry and has gone from being one of the slowest to one of the fastest nations in the adoption of new biotechnologies. The biotech sector is seen in China and internationally as a core area of national scientific and economic development. The main national biotech body in the country is the China National Center for Biotechnology Development. The CNCBD is an organization established on November 3, 1983, under the Ministry of Science and Technology with the approval of the State Council. CNCBD is the sole national center to coordinate and implement the national S&T program in Biotechnology and Health.

<span class="mw-page-title-main">Ohio bioscience sector</span> Significant economic sector in the state

The Ohio bioscience sector strength was ranked #4 among USA states in 2008 by Business Facilities magazine.

A biological patent is a patent on an invention in the field of biology that by law allows the patent holder to exclude others from making, using, selling, or importing the protected invention for a limited period of time. The scope and reach of biological patents vary among jurisdictions, and may include biological technology and products, genetically modified organisms and genetic material. The applicability of patents to substances and processes wholly or partially natural in origin is a subject of debate.

Ryan Bethencourt is an American scientist, entrepreneur, and biohacker best known for his work as co-founder and CEO of Wild Earth, Partner at Babel Ventures and cofounder and former Program Director at IndieBio, a biology accelerator and early stage seed fund. Bethencourt was head of life sciences at the XPRIZE foundation, a co-founder and CEO of Berkeley Biolabs, a biotech accelerator, and Halpin Neurosciences, an ALS therapeutics-focused biotech company. Bethencourt co-founded Counter Culture Labs, a citizen science nonprofit, and Sudo Room, a hacker space based in downtown Oakland, California.

Biotechnology in India is a sunrise sector within the Indian economy. Agencies of the Government of India concerned with the biotechnology industry include the Department of Biotechnology and the proposed Biotechnology Regulatory Authority of India. As of 2022, the sector is valued at $80 billion. Biotechnology in India is in a growth phase and the sector is expected to be valued at $150 billion by 2025 and surpass $300 billion in value by 2030.

<span class="mw-page-title-main">Marek Glezerman</span> Israeli obstetrician and gynecologist

Marek Glezerman is an Israeli obstetrician and gynecologist, Professor Emeritus of Obstetrics and Gynecology, head of Gender and Sex Conscious Medicine and immediate past chair of the Ethics Committee at the Faculty of Medicine, Tel Aviv University. He is the founding president of The Israel Society for Gender and Sex Conscious Medicine and past president of the International Society of Gender Medicine. Glezerman is also a member of the Ministry of Health's National Council for Obstetrics and Gynecology, Genetics and Perinatology. Prof. Glezerman is internationally considered one of the pioneers of Gender and Sex Conscious Medicine.

Shenzhen International BT Leadership Summit is a biology-focused business conference. It is held each year in September. It is arranged by the Shenzhen Municipal People's Government. It is held at the Shenzhen Convention and Exhibition Center.

Varda Shalev is an Israeli medical researcher,a professor of medicine at the Tel Aviv University School of Public Health, and a primary care physician. She is also the co-founder and Chief Medical Officer of Alike. In 11.2022 she became a managing partner at Team8 foundry.

Herald Scholarly Open Access is a publisher of various academic journals. It has a postal address in Herndon, Virginia, United States, but is actually based in Hyderabad, India. Herald Scholarly Open Access has been included on Beall's List of potential predatory open-access publishers, and has faced other criticisms of its publishing practices.

BIOTECanada, or the Industrial Biotechnology Association of Canada, is a Canadian biotechnology industry association based in Ottawa, Ontario. It is an industry-funded membership organization composed of over 250 national and international pharmaceutical and gene therapy companies, medical device manufacturers, agricultural science businesses, law firms, academic institutions, research and development networks, advertising agencies, insurance companies and financial services firms.

References

  1. Garijo, Belen (4 January 2023). "Does the future of science lie in 'bioconvergence'?". World Economic Forum.
  2. 1 2 "Healthcare Bioconvergence Market Size & Share Report, 2030". Grand View Research.
  3. 1 2 3 "The Bio Revolution: Innovations transforming economies, societies, and our lives". McKinsey Global Institute. 13 May 2020.
  4. Garijo, Belén. "Bioconvergence: a multidisciplinary approach to advance human health". Ernst and Young.
  5. "Bioconvergence Revolutionising Life Science and Health Innovation". Innovation Centre Denmark.
  6. World Economic Forum (18 January 2022). "What are the biggest healthcare shifts we'll see in 2022? Here's what health experts think". europeansting.com.
  7. 1 2 "Biodigital Today and Tomorrow". Policy Horizons Canada. 31 May 2022.
  8. Engie, Chris. "The Convergence of Health Care, Biotech, and Technology – and the Location Decisions Behind Them".
  9. "bio-convergence – connecting the innovation systems of the European Union and the State of Israel". kENUP Foundation.
  10. "The Future of Biotech". Office of the Director of National Intelligence. April 2021.
  11. Philippidis, Alex (September 2021). "Buying Spree: Rebranded BICO Bets Big on "Bioconvergence"". Genetic Engineering and Biotechnology News.
  12. "Israel launches 5-year national plan worth $127 mn to boost bio-convergence". Business Standard. 12 May 2022.
  13. "Ben-Gurion University and Soroka Medical Center Announce Strategic Collaboration for Novel Technologies in the Field of Bio-Convergence". Ben-Gurion University of the Negev. 12 May 2022.
  14. "New Center of Innovation at OIST". EurekAlert. 27 October 2022.
  15. "Europe's Bio Revolution Biological Innovations". McKinsey & Company. 10 January 2023.
  16. "Bio-Convergence: The Future of Medicine". Innovation in Israel – 2019 Innovation Report.

Further reading